Peginterferon beta-1a

Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis.
The most common side effects include headache, muscle pain, joint pain, influenza -like symptoms, pyrexia, chills, asthenia, and erythema, pain or pruritus at the injection site.
Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014.

Medical uses

In the United States, peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
In the European Union, peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults.